ClinicalTrials.gg
CompletedNCT03578146Updated Feb 22, 2023Results posted

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

A Phase 2 interventional study of PRT064445/Rivaroxaban and Placebo/Rivaroxaban in Healthy Volunteers, sponsored by Portola Pharmaceuticals. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.

Read the detailed description

A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously administered PRT064445 after dosing to steady state with one of four direct/indirect factor Xa (fXa) inhibitors in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Portola Pharmaceuticals became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men or women between the ages of 18 and 45 years old

Exclusion criteria

Exclusion Criteria:

  • History (including family history) or symptoms of, or risk factors for bleeding
  • History (including family history) of or risk factors for a hypercoagulable or thrombotic condition
  • Absolute/relative to anticoagulation or treatment with specific anticoagulants
  • History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Module 2 (210 mg)

    210 mg andexanet IV bolus administered over 7 minutes (\~30 mg/min)

    Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban

  • Experimental
    Module 2 (420 mg)

    420 mg andexanet IV bolus administered over 14 minutes (\~30 mg/min)

    Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban

  • Experimental
    Module 2 (600 mg)

    600 mg andexanet IV bolus administered over 20 minutes (\~30 mg/min)

    Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban

  • Experimental
    Module 2 (720 mg bolus + 240 mg infusion)

    720 mg IV bolus administered over 24 minutes \[\~30 mg/min\] followed by 240 mg continuous IV infusion \[4 mg/min over 60 min)

    Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban

  • Experimental
    Module 2 (800 mg bolus + 960 mg infusion)

    800 mg IV bolus administered over 26.7 minutes \[\~30 mg/min\] followed by 960 mg continuous IV infusion \[8 mg/min over 120 min\]

    Combination Product: PRT064445/Rivaroxaban · Combination Product: Placebo/Rivaroxaban

  • Experimental
    Module 2 Placebo

    Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.

    Drug: Placebo

Interventions

  • Combination productPRT064445/Rivaroxaban

    Drug pages: PRT064445 · Rivaroxaban

    Also known as: Andexanet

  • Combination productPlacebo/Rivaroxaban
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration

    Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)

    Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration

Secondary outcomes

  1. Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration

    Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.

    Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration

  2. Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration

    Unbound rivaroxaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for rivaroxaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.

    Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration

  3. Andexanet Maximum Observed Plasma Concentration (Cmax)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  4. Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  5. Andexanet Time of Maximum Observed Plasma Concentration (Tmax)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  6. Andexanet Apparent Terminal Elimination Half-life (t1/2)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  7. Andexanet Total Systemic Clearance (CL)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  8. Andexanet Total Volume of Distribution (Vss)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

07

Results

Posted Sep 5, 2018

Participant flow

Subject recruitment occurred at investigative site in the US between March 2013 through April 2014

Participant flow — Overall Study
MilestoneModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Started1666668
Completed1555665
Not completed111003
Withdrew: Did not receive treatment100002
Withdrew: Lost to follow-up011001

Outcome measures

PrimaryEfficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration

Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)

Time frame:
Baseline to 2 minutes following the end of andexanet/placebo administration
Reported as:
Mean · Percent change in anti-fXa activity
Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration
Percent change in anti-fXa activityModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration22.37 ± 42.247-18.09 ± 23.922-50.59 ± 22.056-75.26 ± 19.072-88.91 ± 6.098-92.72 ± 3.084
Statistical analysis
  • Module 2 Placebo vs Module 2 (210 mg) · ANCOVA · p = 0.0121 · Least squares means (difference): -73.14
  • Module 2 Placebo vs Module 2 (420 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): -153.99
  • Module 2 Placebo vs Module 2 (600 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): -189.57
  • Module 2 Placebo vs Module 2 (720 mg Bolus + 240 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): -239.3
  • Module 2 Placebo vs Module 2 (800 mg Bolus + 960 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): -231.12
SecondaryEfficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration

Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.

Time frame:
Baseline to 2 minutes following the end of andexanet/placebo administration
Reported as:
Mean · Percent change in thrombin generation
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
Percent change in thrombin generationModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration14.00 ± 29.267107.47 ± 48.977167.67 ± 36.568246.02 ± 135.387513.85 ± 285.992559.14 ± 288.258
Statistical analysis
  • Module 2 Placebo vs Module 2 (210 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): 52837.94
  • Module 2 Placebo vs Module 2 (420 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): 110388.3
  • Module 2 Placebo vs Module 2 (600 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): 163880.7
  • Module 2 Placebo vs Module 2 (720 mg Bolus + 240 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): 263236.5
  • Module 2 Placebo vs Module 2 (800 mg Bolus + 960 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): 270297.2
SecondaryEfficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration

Unbound rivaroxaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for rivaroxaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.

Time frame:
Baseline to 2 minutes following the end of andexanet/placebo administration
Reported as:
Mean · Percent change in unbound apixaban conc.
Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration
Percent change in unbound apixaban conc.Module 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Efficacy: Percent Change From Baseline in Unbound Rivaroaxaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration-11 ± 1134 ± 2252 ± 1875 ± 1667 ± 2480 ± 12
Statistical analysis
  • Module 2 Placebo vs Module 2 (210 mg) · ANCOVA · p = 0.002 · Least squares means (difference): -9.91
  • Module 2 Placebo vs Module 2 (420 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): -15.06
  • Module 2 Placebo vs Module 2 (600 mg) · ANCOVA · p = <0.0001 · Least squares means (difference): -17.53
  • Module 2 Placebo vs Module 2 (720 mg Bolus + 240 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): -17.05
  • Module 2 Placebo vs Module 2 (800 mg Bolus + 960 mg Infusion) · ANCOVA · p = <0.0001 · Least squares means (difference): -19.33
SecondaryAndexanet Maximum Observed Plasma Concentration (Cmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · ng/mL
Andexanet Maximum Observed Plasma Concentration (Cmax)
ng/mLModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Maximum Observed Plasma Concentration (Cmax)NA ± NA50400 ± 12100105000 ± 28500110000 ± 7070123000 ± 28900161000 ± 40400
SecondaryAndexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · ng*hr/mL
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
ng*hr/mLModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )NA ± NA51400 ± 7520111000 ± 35900133000 ± 11500216000 ± 41300429000 ± 85300
SecondaryAndexanet Time of Maximum Observed Plasma Concentration (Tmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Median · hr
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
hrModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)NA (NA to NA)0.17 (0.16 to 0.41)0.36 (0.29 to 0.52)0.51 (0.39 to 0.83)0.56 (0.44 to 0.70)0.52 (0.49 to 0.73)
SecondaryAndexanet Apparent Terminal Elimination Half-life (t1/2)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · hr
Andexanet Apparent Terminal Elimination Half-life (t1/2)
hrModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Apparent Terminal Elimination Half-life (t1/2)NA ± NA4.97 ± 0.743.91 ± 0.434.54 ± 1.656.47 ± 3.594.45 ± 0.58
SecondaryAndexanet Total Systemic Clearance (CL)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · L/hr
Andexanet Total Systemic Clearance (CL)
L/hrModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Total Systemic Clearance (CL)NA ± NA4.15 ± 0.5564.18 ± 1.514.53 ± 0.3994.58 ± 0.8374.23 ± 0.808
SecondaryAndexanet Total Volume of Distribution (Vss)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · L
Andexanet Total Volume of Distribution (Vss)
LModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Andexanet Total Volume of Distribution (Vss)NA ± NA5.23 ± 1.094.65 ± 1.695.39 ± 0.5464.17 ± 0.7973.34 ± 1.20

Adverse events

Collected over ~7 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Module 2 Placebo—0/15 (0%)12/15 (80%)
Module 2 (210 mg)—0/6 (0%)4/6 (66.7%)
Module 2 (420 mg)—0/6 (0%)3/6 (50%)
Module 2 (600 mg)—0/6 (0%)5/6 (83.3%)
Module 2 (720 mg Bolus + 240 mg Infusion)—0/6 (0%)5/6 (83.3%)
Module 2 (800 mg Bolus + 960 mg Infusion)—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 49
Most frequent other events
EventModule 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)
Infusion-related reactionInjury, poisoning and procedural complications1/151/62/62/63/62/6
Post procedural haematomaInjury, poisoning and procedural complications3/150/61/60/62/60/6
Dizziness posturalNervous system disorders2/150/61/62/61/60/6
HeadacheNervous system disorders3/150/61/62/60/62/6
Dermatitis contactSkin and subcutaneous tissue disorders3/150/60/60/60/60/6
Abdominal tendernessGastrointestinal disorders0/150/60/61/60/60/6
DiarrhoeaGastrointestinal disorders0/150/60/61/60/60/6
Dry mouthGastrointestinal disorders0/151/60/60/60/60/6
ToothacheGastrointestinal disorders0/150/60/61/60/60/6
Catheter site haemorrhageGeneral disorders0/151/60/60/60/60/6

Baseline characteristics

48 subjects were enrolled in this study. Three subjects received rivaroxaban but were discontinued prior to receiving andexanet/placebo due to problems with the infusion pumps observed in prior subjects in the cohort and these subjects were replaced.

Age, Continuous
Age, Continuous(years)Module 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)Total
Mean38.2 ± 6.6935.7 ± 3.3335.7 ± 9.0734.2 ± 7.2535.2 ± 5.0432.9 ± 8.1035.8 ± 6.79
Sex: Female, Male
Sex: Female, Male(Participants)Module 2 PlaceboModule 2 (210 mg)Module 2 (420 mg)Module 2 (600 mg)Module 2 (720 mg Bolus + 240 mg Infusion)Module 2 (800 mg Bolus + 960 mg Infusion)Total
Female3014019
Male136526739
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lu G, Conley PB, Leeds JM, Karbarz MJ, Levy GG, Mathur VS, Castillo J, Crowther M, Curnutte JT. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv. 2020 Feb 25;4(4):728-739. doi: 10.1182/bloodadvances.2019000885. PubMed 32092140 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
Jul 6, 2018
Start
Dec 2012
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Sep 5, 2018
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03578146
Responsible party
Sponsor
First posted
Jul 6, 2018
Start date
Dec 2012
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Sep 5, 2018
Last update
Feb 22, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PRT064445 · Rivaroxaban

Start the discussion